CARBONATE ION

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ACHIRAL
Molecular Formula	CO3
Molecular Weight	60.0089
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	-2

SHOW SMILES / InChI

Structure Search

SMILES

[O-]C([O-])=O

InChI

InChIKey=BVKZGUZCCUSVTD-UHFFFAOYSA-L

InChI=1S/CH2O3/c2-1(3)4/h(H2,2,3,4)/p-2

HIDE SMILES / InChI

Molecular Formula	CH2O3
Molecular Weight	62.0248
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ndrugs.com/?s=kompensan-s%20forte | http://www.catalog.md/drugs/kompensan.html | http://www.nmedication.com/?c=drug&s=kompensan&ingredient=dihydroxyaluminum%20sodium%20carbonate | https://www.ncbi.nlm.nih.gov/pubmed/14367146

Potash (Dihydroxyaluminum Sodium Carbonate), a component of Kompensan-S Forte in Germany, is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Kompensan-S Forte is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Carbonic anhydrase I 62 Target ID: CHEMBL261 Sources: https://www.drugbank.ca/drugs/DB09460	Inhibitor 8297
Carbonic anhydrase II 88 Target ID: CHEMBL205 Sources: https://www.drugbank.ca/drugs/DB09460	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gastrointestinal disorders 95 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14231249 http://www.ndrugs.com/?s=kompensan-s%20forte https://www.ncbi.nlm.nih.gov/pubmed/13952362 https://www.ncbi.nlm.nih.gov/pubmed/13856278	Primary		Approved 8429	Kompensan Approved Use Gastrointestinal disorders: Dyspepsia, Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Hyperphosphatemia

PubMed

Title	Date	PubMed
Studies of neutralizing properties of antacid preparations. Part 4: Application of Weibull distribution function to neutralization of dihydroxyaluminum sodium carbonate.	1988 Jul	3222278
Automation of dihydroxyaluminum sodium carbonate analysis in antacid tablets by energy dispersive X-ray fluorescence.	1990 May-Jun	2376540
Effect of pepsin on the kinetics of HCl neutralization by dihydroxyaluminum sodium carbonate, hydrotalcite and dihydroxyaluminum aminoacetate.	1991	1669540

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Dyspepsia: 500 to 600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Duodenal Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Erosive Esophagitis: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastric Ulcer: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Gastroesophageal Reflux Disease: 500 to 1500 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Zollinger-Ellison Syndrome: 500 to 3600 mg orally 4 to 6 times a day as needed, between meals and at bedtime. Usual Adult Dose for Hyperphosphatemia: 500 to 1000 mg orally 4 times a day, with meals and at bedtime. The dosage should be titrated to the serum phosphate level.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:59:53 GMT 2023` Edited by `admin` on `Fri Dec 15 16:59:53 GMT 2023`
Record UNII	7UJQ5OPE7D
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CARBONATE ION

Common Name

English

Carbonate [WHO-DD]

Common Name

English

CARBONATE

Systematic Name

English

Classification Tree Code System Code

LOINC

2033-9